Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its small-molecule MALT1 inhibitors will be presented during a poster session at the American Society of Hematology (ASH) 63rd Annual Meeting taking place virtually and in Atlanta, Georgia, December 11-14, 2021.

Inhibiting MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is considered a potentially promising therapeutic approach for the treatment of certain subtypes of non-Hodgkin B-cell lymphomas and for chronic lymphocytic leukemia (CLL). Schrödinger has identified a number of small-molecule MALT1 inhibitors, the most advanced of which is expected to enter the clinic next year.

Details of the poster presentation are as follows:

Title: Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

Abstract number: 1187

Date & time: Saturday, December 11, 5:30 p.m. - 7:30 p.m. EST

Location: Georgia World Congress Center, Hall B5

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding the expected timing of clinical trials for Schrödinger’s MALT1 inhibitor program, and the potential of MALT1 inhibitors to be used for the treatment of certain B-cell lymphomas and for chronic lymphocytic leukemia. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "look forward," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond Schrödinger’s control, including the uncertainties inherent in early stage drug development, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and the company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, as well as the other risks and uncertainties identified under the caption "Risk Factors" and elsewhere in the company’s Securities and Exchange Commission filings and reports, including the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2021, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, the company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005073/en/